-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
Börse Tradegate System der Deutsche Börse AG (60%)EURSymbol EX9-
EXELIXIS INCBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol EX9
-
EXELIXIS INCBörse Gettex System der Börse MünchenEURSymbol EX9
-
EXELIXIS INCBörse Börse StuttgartEURSymbol EX9
-
ExelixisBörse NasdaqISIN US30161Q1040 WKN: 936718Symbol EXEL
-
ISIN US30161Q1040 WKN: 936718USDSymbol EXEL
-
EURSymbol EX9
-
Symbol EX9
-
Symbol EX9
-
Symbol EX9
-
Exelixis, Inc.Börse London Stock Exchange
-
Symbol EX9
Währung
EUR
Börse
Tradegate System der Deutsche Börse AG (60%) Zeitzone: Europe/Berlin
Firmenname
Exelixis, Inc
Marktkapitalisierung
6.607.350.624 (+- 3%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
6.835.701.248 oder 6.379.000.000
Mitarbeiter
920 (+- 33%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
617 oder 1.223 Mitarbeiter
KGV
62.6
EBITDA 121.901.000
PEGRatio 1.1761
Buchwert 6.03
Entdecke die 6 ETFs in denen Exelixis, Inc am höchsten gewichtet ist Insgesamt in 9 ETFs enthalten
Dir gefallen die Informationen zu Exelixis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Exelixis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Exelixis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Exelixis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
38 News & Informationen zur Exelixis Aktie
Exelixis, Inc. 2021 Q2 – Results – Earnings Call Presentation (NASDAQ:EXEL)
The following slide deck was published by Exelixis, Inc.
Exelixis (EXEL) Beats on Q2 Earnings & Revenues, Ups Sales View
Exelixis (EXEL) beats on both earnings and revenues in the second quarter. Both figures increase on a year-over-year basis.
Exelixis, Inc. (EXEL) CEO Mike Morrissey on Q2 2021 Results – Earnings Call Transcript
Exelixis, Inc. (NASDAQ:EXEL) Q2 2021 Earnings Conference Call August 5, 2021 05:00 PM ET Company Participants Susan Hubbard – Executive Vice President of Public Affairs & Investor…
Exelixis EPS beats by $0.24, beats on revenue (NASDAQ:EXEL)
Exelixis (EXEL): Q2 Non-GAAP EPS of $0.37; GAAP EPS of $0.30 beats by $0.24.Revenue of $385.18M (+48.4% Y/Y) beats by $85.15M.Cash, cash equivalents, restricted cash equivalents…
Exelixis : Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differe
– U.S. Food and Drug Administration assigned a Prescription Drug User Fee Act action date of December 4, 2021 –
– The supplemental New Drug Application is based on the phase 3… | August 5, 2021
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of …
Earnings Preview: Exelixis (EXEL) Q2 Earnings Expected to Decline
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Were Hedge Funds Right About Dumping Royal Gold, Inc (RGLD)?
In this article we will analyze whether Royal Gold, Inc (NASDAQ:RGLD) is a good investment right now by following the lead of some of the best investors…
5 No-Brainer Stocks to Invest $500 In Right Now
You don't need a mountain of cash to build wealth on Wall Street.
DGAP-News: Il settore delle biotecnologie -2-
scienza. Il team di gestione di BB Biotech intende sfruttare questa tendenza in maniera mirata, ampliando le proprie
competenze negli ambiti di advanced analytics e intelligenza artificiale…. | July 23, 2021
Tempest Therapeutics : BUSINESS (Form 8-K)
TEMPEST'S BUSINESS
Overview
Tempest is a clinical-stage oncology company focused on leveraging its deep scientific understanding of cancer… | July 16, 2021
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 68 companies hit new 52-week lows.
Points of Interest: TotalEnergies (NYSE:TTE) was the biggest company by market cap to …
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ju…
The Smartest Stocks to Buy With $20 in July
You don't need a lot of cash to begin or further your trek toward financial independence.
Hedge Funds Are Souring On Sealed Air Corporation (SEE)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data….
After Plummeting More Than 23%, Is Exelixis a Buy?
The market may have overreacted to weak clinical trial data, but its pessimism wasn't entirely misplaced.
Is Exelixis Stock a Buy After Its Disappointing Liver Cancer Study Results?
The biotech stock plunged after disappointing clinical results.
Exelixis : to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021
– Presentation to be webcast on http://www.exelixis.com –
… | July 8, 2021
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 158 companies reached new 52-week lows.
Noteworthy Highlights: The largest company in terms of market cap to set a new …
Global $79.2 Billion Kinase Inhibitors Markets to 2026: Antineoplastic Agents, Age-related Macular Degeneration (AMD), Immunosuppressant
/PRNewswire/ — The
Global $79.2 Billion Kinase Inhibitors Markets To 2026: Antineoplastic Agents, Age-related Macular Degeneration (AMD), Immunosuppressant
DUBLIN, July 2, 2021 /PRNewswire/ — The
The Smartest Stocks to Buy With $100 for the Second Half of 2021
You don't need to start with a fortune to make one on Wall Street.
Will Exelixis Stock See Even Lower Levels After Negative Data From A Clinical Trial?
The stock price of Exelixis, a genomics-based pharmaceuticals company focused on oncology treatments, has seen a large 21% drop over the last five trading days, after the company announced a negative outcome from its clinical trials for Cabometyx in previously untreated liver cancer patients…
Exelixis (EXEL) Down on Data from Ongoing Liver Cancer Study
Exelixis (EXEL) and partner announce unimpressive data from the late-stage COSMIC-312 study in patients with previously untreated advanced hepatocellular carcinoma.
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.44% By Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.44%
Etsy, Intellia rise; Carnival, Exelixis fall
Stocks that traded heavily or had substantial price changes Monday: Etsy, Intellia rise; Carnival, Exelixis fall
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to …
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0….
Here's Why Exelixis Stock Is Dropping Today
The company reported successful clinical trial results, but investors were still disappointed.
Where Do Hedge Funds Stand On Sotera Health Company (SHC)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings…
Ipsen : Exelixis_COSMIC-312 TLR – 28 June 2021.pdf
Investors Contact:
Ipsen Investor Contact:
… | June 28, 2021
Exelixis : and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Prev
Exelixis, Inc. and Ipsen today announced that COSMIC-312, the ongoing phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in patients with previously… | June 28, 2021
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment. Eli Lilly and Company (…
Evaluating Exelixis (NASDAQ:EXEL)
Exelixis, Inc.'s (EXEL) Management Presents at 39th Annual JPMorgan Healthcare Conference (Transcript)
Exelixis : Announces Preliminary Fourth Quarter and Full Year 2020 Financial Results, Provides 2021 Financial Guidance, and Outlines Key Priorities and Anticipated Milestones For 2021
– Cabozantinib Franchise Preliminary Net Product Revenue of $200 million for the Fourth Quarter 2020, and $741 million for the Full Year 2020 –
– Full Year 2021 Net Product Revenue… | January 10, 2021
3 Top Biotech Picks for 2021
One big biotech and two small biotechs that share a common denominator: Great growth prospects.
Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint
— Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and …